Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX)
1.7200
-1.1700 (-40.48%)
NYSE · Last Trade: May 10th, 1:34 PM EDT
Detailed Quote
Previous Close
2.890
Open
2.390
Bid
1.750
Ask
1.760
Day's Range
1.720 - 2.390
52 Week Range
0.8214 - 3.100
Volume
5,949,698
Market Cap
126.65M
PE Ratio (TTM)
43.00
EPS (TTM)
0.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,016,789
Chart
About Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX)
Protalix Biotherapeutics is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of rare and chronic diseases. Utilizing its proprietary oral protein manufacturing platform, the company works to produce biopharmaceuticals that can provide effective treatment alternatives for patients. Protalix is particularly dedicated to addressing unmet medical needs and improving the quality of life for individuals suffering from conditions such as enzyme deficiencies, leveraging its expertise in biochemistry and molecular biology to advance its therapeutic pipeline. Read More
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.
A fundamental and technical analysis of (NYSEARCA:PLX): PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) may be suited for high growth investing, we'll explore why in this article.
RALEIGH, NC / ACCESS Newswire / March 21, 2025 / iAccess Alpha's Virtual Best Ideas Spring Investment Conference will take place on March 25-26, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights and investing opportunities.
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.
PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Notable NFT news this week is from video game retailer GameStop, which has announced its NFT marketplace will shut down next month. The publicly-traded company is citing “regulatory uncertainty” for its decision to discontinue the NFT business.
